TORONTO, March 30, 2016 /PRNewswire/ - Merus Labs International Inc. (“Merus” or the “Company”) [TSX: MSL, NASDAQ: MSLI] reported today the results of its 2016 annual general meeting of shareholders held on March 30, 2016.
All directors nominated as listed in the Company’s management information circular dated February 26, 2016 were re-elected as members of the board as follows:
Director | Votes For | % For | Withheld Votes | % |
Michael Cloutier | 48,379,697 | 98.28% | 848,566 | 1.72% |
Robert S. Pollock | 47,798,438 | 97.10% | 1,429,825 | 2.90% |
Timothy G. Sorensen | 47,797,737 | 97.09% | 1,430,526 | 2.91% |
David D. Guebert | 47,796,057 | 97.09% | 1,432,206 | 2.91% |
Theresa Firestone | 47,598,927 | 96.69% | 1,629,336 | 3.31% |
Barry Fishman | 48,401,638 | 98.32% | 826,625 | 1.68% |
Robert Bloch | 49,146,998 | 99.83% | 81,265 | 0.17% |
In addition, shareholders approved the appointment of MNP LLP,
Chartered Accountants, as the auditor of Merus to hold office until the next annual meeting of shareholders.
About Merus Labs
Merus Labs is a specialty pharmaceutical company focused on acquiring established products. The Company leverages its expertise and commercial platform in Europe, Canada and select other markets to deliver value.
SOURCE Merus Labs International Inc.
